Download PDF
Semin Neurol 2016; 36(01): 092-098
DOI: 10.1055/s-0036-1571443
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Use of Botulinum Toxin in the Management of Headache Disorders

Stephen D. Silberstein
1   Jefferson Headache Center, Thomas Jefferson University, Philadelphia, Pennsylvania
› Author Affiliations
Further Information

Publication History

Publication Date:
11 February 2016 (online)

    Permissions and Reprints

Abstract

Headache disorders can be further classified as episodic (< 15 headache days per month) or chronic (≥15 headache days per month for more than 3 months). Chronic migraine (CM) requires that headaches occur on 15 or more days a month for more than 3 months. These headaches must be migraines on at least 8 days per month. There are seven botulinum toxin (BoNT) serotypes (A1, A2, A3, B, C1, D, E, F, and G). All serotypes inhibit acetylcholine release, although their intracellular target proteins, physiochemical characteristics, and potencies are different. Its mechanism of action in pain is being investigated. Botulinum toxin type A (BoNT-A) has been the most widely studied serotype for therapeutic purposes. A major clinical advantage of type A toxin arises from its prolonged duration of action due to the longevity of its protease (90 days in rats and probably much longer in human neurons). Clinical studies suggest that BoNT is a safe treatment and is efficacious for the prevention of some forms of migraine, such as CM, and perhaps high-frequency episodic migraine.

Keywords

migraine - chronic migraine - botulinum toxin - prevention
 

  • References

  • 1 National Institute of Neurological Disorders and Stroke (NINDS). Headache: Hope Through Research. NIH Publication 02–158. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health; 2002
    Google Scholar
  • 2 Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 3rd Edition, Beta Version. Cephalalgia 2013; 33 (9) 629-808
    CrossrefPubMedGoogle Scholar
  • 3 Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55 (6) 754-762
    CrossrefPubMedGoogle Scholar
  • 4 Silberstein SD. Migraine. Lancet 2004; 363 (9406) 381-391
    CrossrefPubMedGoogle Scholar
  • 5 Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41 (7) 646-657
    CrossrefPubMedGoogle Scholar
  • 6 World Health Organization. Headache Disorders. Fact Sheet No 277. 2007. Available at: http://www.who.int/mediacentre/factsheets/fs277/en/print.html . Accessed January 1, 2016
    PubMedGoogle Scholar
  • 7 Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999; 159 (8) 813-818
    CrossrefPubMedGoogle Scholar
  • 8 Silberstein SD, Stark SR, Lucas SM, Christie SN, Degryse RE, Turkel CC ; BoNTA-039 Study Group. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005; 80 (9) 1126-1137
    CrossrefPubMedGoogle Scholar
  • 9 Scher AI, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache 1998; 38 (7) 497-506
    CrossrefPubMedGoogle Scholar
  • 10 Castillo J, Muñoz P, Guitera V, Pascual J Kaplan Award 1998. Epidemiology of chronic daily headache in the general population. Headache 1999; 39 (3) 190-196
    CrossrefPubMedGoogle Scholar
  • 11 Wang SJ, Fuh JL, Lu SR , et al. Chronic daily headache in Chinese elderly: prevalence, risk factors, and biannual follow-up. Neurology 2000; 54 (2) 314-319
    CrossrefPubMedGoogle Scholar
  • 12 Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache 2003; 43 (4) 336-342
    CrossrefPubMedGoogle Scholar
  • 13 Meletiche DM, Lofland JH, Young WB. Quality-of-life differences between patients with episodic and transformed migraine. Headache 2001; 41 (6) 573-578
    CrossrefPubMedGoogle Scholar
  • 14 Lipton RB, Varon SF, Grosberg B , et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology 2011; 77 (15) 1465-1472
    CrossrefPubMedGoogle Scholar
  • 15 Schwartz BS, Stewart WF, Simon D, Lipton RB. Epidemiology of tension-type headache. JAMA 1998; 279 (5) 381-383
    CrossrefPubMedGoogle Scholar
  • 16 Silberstein SD, Lipton RB, Dodick DW. Wolff's Headache and Other Head Pain. 8th ed. New York: Oxford University Press; 2008
    Google Scholar
  • 17 Silberstein SD, Göbel H, Jensen R , et al. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia 2006; 26 (7) 790-800
    CrossrefPubMedGoogle Scholar
  • 18 Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E ; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78 (17) 1337-1345
    CrossrefPubMedGoogle Scholar
  • 19 Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E ; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78 (17) 1346-1353
    CrossrefPubMedGoogle Scholar
  • 20 Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache 2015; 55 (1) 3-20
    CrossrefPubMedGoogle Scholar
  • 21 Blumenfeld AM, Binder W, Silberstein SD, Blitzer A. Procedures for administering botulinum toxin type A for migraine and tension-type headache. Headache 2003; 43 (8) 884-891
    CrossrefPubMedGoogle Scholar
  • 22 Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 2001; 8 (Suppl. 05) 21-29
    CrossrefPubMedGoogle Scholar
  • 23 Mauskop A. The use of botulinum toxin in the treatment of headaches. Pain Physician 2004; 7 (3) 377-387
    PubMedGoogle Scholar
  • 24 Wang J, Zurawski TH, Meng J , et al. A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic. J Biol Chem 2011; 286 (8) 6375-6385
    CrossrefPubMedGoogle Scholar
  • 25 BOTOX. Irvine, CA: Allergan, Inc.; 2013. . Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/ucm176360.pdf
    Google Scholar
  • 26 Dysport®. Basking Ridge, NJ: Ipsen Biopharmaceuticals, Inc.; 2015. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM165110.pdf
    PubMedGoogle Scholar
  • 27 Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 2000; 123 (6) 669-676
    CrossrefPubMedGoogle Scholar
  • 28 Jensen R, Bendtsen L, Olesen J. Muscular factors are of importance in tension-type headache. Headache 1998; 38 (1) 10-17
    CrossrefPubMedGoogle Scholar
  • 29 Jakubowski M, McAllister PJ, Bajwa ZH, Ward TN, Smith P, Burstein R. Exploding vs. imploding headache in migraine prophylaxis with botulinum toxin A. Pain 2006; 125 (3) 286-295
    CrossrefPubMedGoogle Scholar
  • 30 Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD ; BOTOX CDH Study Group. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 2005; 45 (4) 315-324
    CrossrefPubMedGoogle Scholar
  • 31 Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003; 43 (Suppl. 01) S9-S15
    CrossrefPubMedGoogle Scholar
  • 32 Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004; 107 (1–2) 125-133
    CrossrefPubMedGoogle Scholar
  • 33 Oshinsky M, Poso-Rosich P, Luo J, Hyman S, Silberstein SD. Botulinum toxin A blocks sensitization of neurons in the trigeminal nucleus caudalis. Cephalalgia 2004; 24: 781 (Abstract)
    PubMedGoogle Scholar
  • 34 Matak I, Rossetto O, Lacković Z. Botulinum toxin type A selectivity for certain types of pain is associated with capsaicin-sensitive neurons. Pain 2014; 155 (8) 1516-1526
    CrossrefPubMedGoogle Scholar
  • 35 Burstein R, Zhang X, Levy D, Aoki KR, Brin MF. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. Cephalalgia 2014; 34 (11) 853-869
    CrossrefPubMedGoogle Scholar
  • 36 Schulte-Mattler WJ, Leinisch E. Evidence based medicine on the use of botulinum toxin for headache disorders. J Neural Transm (Vienna) 2008; 115 (4) 647-651
    CrossrefPubMedGoogle Scholar
  • 37 Silberstein S, Mathew N, Saper J, Jenkins S ; For the BOTOX Migraine Clinical Research Group. Botulinum toxin type A as a migraine preventive treatment. Headache 2000; 40 (6) 445-450
    CrossrefPubMedGoogle Scholar
  • 38 Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt IW, Frese A. Botulinum toxin A in the prophylactic treatment of migraine—a randomized, double-blind, placebo-controlled study. Cephalalgia 2004; 24 (10) 838-843
    CrossrefPubMedGoogle Scholar
  • 39 Saper JR, Mathew NT, Loder EW, DeGryse R, VanDenburgh AM ; BoNTA-009 Study Group. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine. Pain Med 2007; 8 (6) 478-485
    CrossrefPubMedGoogle Scholar
  • 40 Elkind AH, O'Carroll P, Blumenfeld A, DeGryse R, Dimitrova R ; BoNTA-024-026-036 Study Group. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain 2006; 7 (10) 688-696
    CrossrefPubMedGoogle Scholar
  • 41 Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C ; BOTOX CDH Study Group. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005; 45 (4) 293-307
    CrossrefPubMedGoogle Scholar
  • 42 Aurora SK, Dodick DW, Turkel CC , et al; PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30 (7) 793-803
    CrossrefPubMedGoogle Scholar
  • 43 Diener HC, Dodick DW, Aurora SK , et al; PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30 (7) 804-814
    CrossrefPubMedGoogle Scholar
  • 44 Dodick DW, Turkel CC, DeGryse RE , et al; PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50 (6) 921-936
    CrossrefPubMedGoogle Scholar
  • 45 Rozen D, Sharma J. Treatment of tension-type headache with botox: a review of the literature. Mt Sinai J Med 2006; 73 (1) 493-498
    PubMedGoogle Scholar